Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Next Previous
X
Search
Trial Profile

A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Acronyms CIBS
  • Sponsors Synergy Pharmaceuticals Inc

    • Most Recent Events

    • 28 Oct 2020 Results assessing efficacy of Plecanatide from 4 phase 3 trials presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020
    • 22 Oct 2014 Results presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology.
    • 21 Oct 2014 As per the media release issued in October 2014, the company has successfully completed an end-of-phase 2 meeting with the FDA for this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top